TY - JOUR
T1 - Strong and Specific Protective and Therapeutic Immunity Induced by Single HLA-A2.1 Restricted Epitope DNA Vaccine in Rabbits
AU - Hu, Jiafen
AU - Schell, Todd D.
AU - Peng, Xuwen
AU - Cladel, Nancy M.
AU - Balogh, Karla K.
AU - Christensen, Neil D.
N1 - Funding Information:
We thank Martin Pickel and Jeremy Haley for excellent help with the animals. This work was supported by the National Cancer Institute grant RO1 CA47622 from the National Institutes of Health and the Jake Gittlen Memorial Golf Tournament. Table 1. Partial and complete protection stimulated by CRPVE1/161-169 and CRPVE1/303-311 epitope DNA vaccination in outbred HLA-A2.1 transgenic rabbits
PY - 2009
Y1 - 2009
N2 - An HLA-A2.1 transgenic rabbit /Cottontail rabbit papillomavirus (CRPV) infection model has been reported previously. In this study, we incorporated online MHCI epitope prediction software and HLA-A2.1 transgenic mouse and rabbit systems together to demonstrate an efficient way to identify and test immunogenicity of two HLA-A2.1 restricted epitopes from CRPVE1 (161-169 LLFRQAHSV and 303-311 MLQEKPFQL). Both epitopes were able to induce specific cytotoxic CD8 T cells in HLA-A2.1 mice and rabbits after peptide and DNA immunization and in vitro stimulation respectively. Using an epitope DNA vaccination method, we achieved partial and complete protection against CRPV DNA challenge by CRPVE1/161-169 and CRPVE1/303-311 respectively in HLA-A2.1 transgenic outbred rabbits. CRPVE1/303-311 also showed strong and specific therapeutic effects in CRPV-infected HLA-A2.1 transgenic outbred rabbits. Interestingly, epitope CRPVE1/303-311 (but not E1/161-169) showed strong protective immunity in non-transgenic EIII/JC inbred (but not outbred) NZW rabbits. Our data demonstrates an efficient way to identify HLA-A2.1 restricted epitopes for the development of prophylactic and therapeutic vaccines.
AB - An HLA-A2.1 transgenic rabbit /Cottontail rabbit papillomavirus (CRPV) infection model has been reported previously. In this study, we incorporated online MHCI epitope prediction software and HLA-A2.1 transgenic mouse and rabbit systems together to demonstrate an efficient way to identify and test immunogenicity of two HLA-A2.1 restricted epitopes from CRPVE1 (161-169 LLFRQAHSV and 303-311 MLQEKPFQL). Both epitopes were able to induce specific cytotoxic CD8 T cells in HLA-A2.1 mice and rabbits after peptide and DNA immunization and in vitro stimulation respectively. Using an epitope DNA vaccination method, we achieved partial and complete protection against CRPV DNA challenge by CRPVE1/161-169 and CRPVE1/303-311 respectively in HLA-A2.1 transgenic outbred rabbits. CRPVE1/303-311 also showed strong and specific therapeutic effects in CRPV-infected HLA-A2.1 transgenic outbred rabbits. Interestingly, epitope CRPVE1/303-311 (but not E1/161-169) showed strong protective immunity in non-transgenic EIII/JC inbred (but not outbred) NZW rabbits. Our data demonstrates an efficient way to identify HLA-A2.1 restricted epitopes for the development of prophylactic and therapeutic vaccines.
UR - http://www.scopus.com/inward/record.url?scp=71549116707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71549116707&partnerID=8YFLogxK
U2 - 10.1016/j.provac.2009.07.003
DO - 10.1016/j.provac.2009.07.003
M3 - Article
AN - SCOPUS:71549116707
SN - 1877-282X
VL - 1
SP - 4
EP - 14
JO - Procedia in Vaccinology
JF - Procedia in Vaccinology
IS - 1
ER -